How Effective is the Automation and Validating of Human Dose Predictive Models?
Dose prediction is a critical part of drug discovery which determines the safety and efficacy of drugs within patients. Dose response predictions are made with preclinical models which quantify pharmacokinetic (PK) behaviour via a number of parameters. Despite the continuous...
1 year agoHow Effective is the Automation and Validating of Human Dose Predictive Models?
Dose prediction is a critical part of drug discovery which determines the safety and efficacy of drugs within patients. Dose response predictions are made with preclinical models which quantify pharmacokinetic (PK) behaviour via a number of parameters. Despite the continuous...
1 year ago
Predicting Drug Toxicity: Challenges and Innovations
Failure to reach the desired safety profile is one of the main reasons for delayed drug development. Advancements in preclinical studies have seen the optimisation of in vitro assays to better predict toxicity in drug discovery. Computational methods like in...
1 year agoPredicting Drug Toxicity: Challenges and Innovations
Failure to reach the desired safety profile is one of the main reasons for delayed drug development. Advancements in preclinical studies have seen the optimisation of in vitro assays to better predict toxicity in drug discovery. Computational methods like in...
1 year ago
A Look Ahead: Clinical Trials and PV Over the Next 5 Years
Given the severity of industry disruptions in 2020, and the surge in innovation and development that followed, the future of clinical operations seems more clouded than ever. Proventa set out to find out more about the future of Clinical Trials...
1 year agoA Look Ahead: Clinical Trials and PV Over the Next 5 Years
Given the severity of industry disruptions in 2020, and the surge in innovation and development that followed, the future of clinical operations seems more clouded than ever. Proventa set out to find out more about the future of Clinical Trials...
1 year ago
The Future of Clinical Trials and Pharmacovigilance
This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Clinical Trials/Pharmacovigilance...
2 years agoThe Future of Clinical Trials and Pharmacovigilance
This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Clinical Trials/Pharmacovigilance...
2 years ago
Antibiotic Resistance: Is Pharma Doing Enough?
Developed resistances to certain antibiotics have occurred since their creation in the 1940s. Scientists found the first case of resistance just four years after antibiotics entered mass production. Only recently, however, has the issue taken a critical turn. Resistant strains of...
3 years agoAntibiotic Resistance: Is Pharma Doing Enough?
Developed resistances to certain antibiotics have occurred since their creation in the 1940s. Scientists found the first case of resistance just four years after antibiotics entered mass production. Only recently, however, has the issue taken a critical turn. Resistant strains of...
3 years ago
AI and Pharmacovigilance ADR processing
Many of the problems that have long been inherent in Pharmacovigilance (PV) - such as historic limitations in the information that is published in case reports, analysis of electronic health records and integration - have found an answer in the...
3 years agoAI and Pharmacovigilance ADR processing
Many of the problems that have long been inherent in Pharmacovigilance (PV) - such as historic limitations in the information that is published in case reports, analysis of electronic health records and integration - have found an answer in the...
3 years ago
The Abbvie-Allergan Deal: A Matter of Distrust?
Compared to the merger announcement itself, the industry reaction to the $63 billion Abbvie buyout of Allergan, announced this June, was no big surprise. Abbvie, seeking to replace its now-ageing blockbuster drug Humira, was the only suitor for the Botox...
3 years agoThe Abbvie-Allergan Deal: A Matter of Distrust?
Compared to the merger announcement itself, the industry reaction to the $63 billion Abbvie buyout of Allergan, announced this June, was no big surprise. Abbvie, seeking to replace its now-ageing blockbuster drug Humira, was the only suitor for the Botox...
3 years ago